Posaconazole-induced Pseudohyperaldosteronism

Jutamart Tantiprawan¹, Sarat Sunthornyothin^{1

2}, Patchaya Boonchaya-Anant^{1

2}, Thiti Snabboon^{1

2}

Affiliations

¹ Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
² Excellence Center in Diabetes, Hormone, and Metabolism, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Case Reports

Jutamart Tantiprawan et al. Kaohsiung J Med Sci. 2021 Mar.

. 2021 Mar;37(3):253-254.

doi: 10.1002/kjm2.12325. Epub 2020 Nov 24.

Jutamart Tantiprawan¹, Sarat Sunthornyothin^{1

2}, Patchaya Boonchaya-Anant^{1

2}, Thiti Snabboon^{1

2}

¹ Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
² Excellence Center in Diabetes, Hormone, and Metabolism, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

No abstract available

References

1. Boughton C, Taylor D, Ghataore L, Taylor N, Whitelaw BC. Mineralocorticoid hypertension and hypokalaemia induced by posaconazole. Endocrinol Diabetes Metab Case Rep. 2018;2018:17–157. - PMC - PubMed
1. Thompson GR 3rd, Beck KR, Patt M, Kratschmar DV, Odermatt A. Posaconazole‐induced hypertension due to inhibition of 11β‐hydroxylase and 11β‐hydroxysteroid dehydrogenase 2. J Endocr Soc. 2019;3(7):1361–1366. - PMC - PubMed
1. Nguyen MH, Davis MR, Wittenberg R, Mchardy I, Baddley JW, Young BY, et al. Posaconazole serum drug levels associated with pseudohyperaldosteronism. Clin Infect Dis. 2020;70(12):2593–2598. - PMC - PubMed
1. Kosmidis C, Rodriguez‐Goncer I, Rautemaa‐Richardson R, Richardson MD, Moore CB, Denning DW. Therapeutic drug monitoring and adverse events of delayed‐release posaconazole tablets in patients with chronic pulmonary aspergillosis. J Antimicrob Chemother. 2019;74(4):1056–1061. - PubMed
1. Davis MR, Nguyen MH, Gintjee TJ, Odermatt A, Young BY, Thompson GR. Management of posaconazole‐induced pseudohyperaldosteronism. J Antimicrob Chemother. 2020;dkaa366. 10.1093/jac/dkaa366. - DOI - PubMed